117 related articles for article (PubMed ID: 17963703)
41. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
42. The molecular mechanism of cholestatic pruritus.
Oude Elferink RP; Kremer AE; Martens JJ; Beuers UH
Dig Dis; 2011; 29(1):66-71. PubMed ID: 21691108
[TBL] [Abstract][Full Text] [Related]
43. Autotaxin enzyme immunoassay in human cerebrospinal fluid samples.
Nakamura K; Ohkawa R; Okubo S; Yokota H; Ikeda H; Yatomi Y; Igarashi K; Ide K; Kishimoto T; Masuda A; Yamamoto T; Tsuji S; Saito N; Kurokawa M; Okudaira S; Aoki J
Clin Chim Acta; 2009 Jul; 405(1-2):160-2. PubMed ID: 19414005
[No Abstract] [Full Text] [Related]
44. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells.
Jansen S; Andries M; Vekemans K; Vanbilloen H; Verbruggen A; Bollen M
Cancer Lett; 2009 Nov; 284(2):216-21. PubMed ID: 19482419
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical detection of autotaxin (ATX)/lysophospholipase D (lysoPLD) in submucosal invasive colorectal cancer.
Kazama S; Kitayama J; Aoki J; Mori K; Nagawa H
J Gastrointest Cancer; 2011 Dec; 42(4):204-11. PubMed ID: 20623382
[TBL] [Abstract][Full Text] [Related]
46. Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids.
Nakamura K; Kishimoto T; Ohkawa R; Okubo S; Tozuka M; Yokota H; Ikeda H; Ohshima N; Mizuno K; Yatomi Y
Anal Biochem; 2007 Aug; 367(1):20-7. PubMed ID: 17568554
[TBL] [Abstract][Full Text] [Related]
47. Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts.
Parrill AL; Baker DL
Expert Opin Ther Pat; 2010 Dec; 20(12):1619-25. PubMed ID: 21047298
[TBL] [Abstract][Full Text] [Related]
48. HIV-1 Tat Inhibits Autotaxin Lysophospholipase D Activity and Modulates Oligodendrocyte Differentiation.
Wheeler NA; Fuss B; Knapp PE; Zou S
ASN Neuro; 2016 Oct; 8(5):. PubMed ID: 27659560
[TBL] [Abstract][Full Text] [Related]
49. High expression of autotaxin is associated with poor recurrence-free survival in cholangiocarcinoma.
Li X; Koyama Y; Taura K; Nishio T; Yoh T; Nishino H; Uemoto Y; Kimura Y; Nakamura D; Nam NH; Sato M; Seo S; Iwaisako K; Hatano E
Hepatol Res; 2024 Mar; ():. PubMed ID: 38430513
[TBL] [Abstract][Full Text] [Related]
50. Pseudohypocalcemia in Cancer Patients: A Recommendation for the Postanalytical Correction of Serum Calcium in Patients with Hypoalbuminemia.
Carroll B; Fleisher M; Pessin MS; Richardson S; Ramanathan LV
Clin Chem; 2017 Jul; 63(7):1302-1304. PubMed ID: 28515104
[No Abstract] [Full Text] [Related]
51. Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy.
Kremer AE; Bolier R; Dixon PH; Geenes V; Chambers J; Tolenaars D; Ris-Stalpers C; Kaess BM; Rust C; van der Post JA; Williamson C; Beuers U; Oude Elferink RP
J Hepatol; 2015 Apr; 62(4):897-904. PubMed ID: 25450205
[TBL] [Abstract][Full Text] [Related]
52. Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease.
Iwadare T; Kimura T; Okumura T; Wakabayashi SI; Nakajima T; Kondo S; Kobayashi H; Yamashita Y; Sugiura A; Fujimori N; Yamazaki T; Kunimoto H; Shimamoto S; Igarashi K; Joshita S; Tanaka N; Umemura T
Commun Med (Lond); 2024 Apr; 4(1):73. PubMed ID: 38627520
[TBL] [Abstract][Full Text] [Related]
53. Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation.
Takemura K; Nakamae M; Okamura H; Sakatoku K; Ido K; Makuuchi Y; Kuno M; Takakuwa T; Hirose A; Nishimoto M; Nakashima Y; Koh H; Igarashi K; Kubota H; Hino M; Nakamae H
Ann Hematol; 2024 May; 103(5):1705-1715. PubMed ID: 38494552
[TBL] [Abstract][Full Text] [Related]
54. Development of an advanced liquid chromatography-tandem mass spectrometry measurement system for simultaneous sphingolipid analysis.
Uranbileg B; Sakai E; Kubota M; Isago H; Sumitani M; Yatomi Y; Kurano M
Sci Rep; 2024 Mar; 14(1):5699. PubMed ID: 38459112
[TBL] [Abstract][Full Text] [Related]
55. Role of autotaxin in systemic lupus erythematosus.
Tsuchida Y; Shoda H; Sawada T; Fujio K
Front Med (Lausanne); 2023; 10():1166343. PubMed ID: 37122329
[TBL] [Abstract][Full Text] [Related]
56. Circulating autotaxin levels in healthy teenagers: Data from the Vitados cohort.
Méaux MN; Regnier M; Portefaix A; Borel O; Alioli C; Peyruchaud O; Legrand M; Bacchetta J
Front Pediatr; 2023; 11():1094705. PubMed ID: 36861069
[TBL] [Abstract][Full Text] [Related]
57. Apolipoprotein D modulates lipid mediators and osteopontin in an anti-inflammatory direction.
Kurano M; Tsukamoto K; Kamitsuji S; Kamatani N; Hasegawa K; Hara M; Ishikawa T; Yatomi Y; Teramoto T
Inflamm Res; 2023 Feb; 72(2):263-280. PubMed ID: 36536251
[TBL] [Abstract][Full Text] [Related]
58. Decrease in serum levels of autotaxin in COVID-19 patients.
Shimura T; Kurano M; Okamoto K; Jubishi D; Hashimoto H; Kano K; Igarashi K; Shimamoto S; Aoki J; Moriya K; Yatomi Y
Ann Med; 2022 Dec; 54(1):3189-3200. PubMed ID: 36369824
[TBL] [Abstract][Full Text] [Related]
59. Role of Autotaxin in High Glucose-Induced Human ARPE-19 Cells.
Liu Y; Yamagishi R; Honjo M; Kurano M; Yatomi Y; Igarashi K; Aihara M
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012446
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
